Pfizer (NYSE:PFE) has expanded its obesity drug ambitions with the acquisition of Metsera and more than 20 active clinical studies in weight management. The company also reported promising pivotal ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Pfizer Inc. has acquired exclusive rights to commercialize an obesity therapy in China, strengthening its push into the ...

Pfizer Inc. (NYSE:PFE) is among the Best Affordable Stocks Under $40 to Buy. On February 17, Pfizer Inc. (NYSE:PFE) announced ...

Johnson & Johnson is upgraded to Buy and Pfizer to Hold reflecting improved profitability outlooks post-Q4 2025 earnings.

Fintel reports that on February 20, 2026, Barclays initiated coverage of Pfizer (NYSE:PFE) with a Underweight recommendation. Analyst Price Forecast Suggests 9.96% Upside As of February 4, 2026, the ...

Sciwind said the agreement marks “an important first step to advance Pfizer's global strategy in the metabolic field in China,” according ...

The nicotine gum market presents opportunities through rising anti-smoking campaigns, demand for convenient cessation solutions, flavored variants, and online channels. Innovations like lozenges ...

BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product ...